JPRN-UMIN000009733已完成2 期
A phase 2 study of nab-Paclitaxel followed by FEC (Fluorouracil, Epirubicin, Cyclophosphamide) as primary therapy for operable breast cancer - A phase 2 study of nab-Paclitaxel followed by FEC (Fluorouracil, Epirubicin, Cyclophosphamide) as primary therapy for operable breast cancer
Hiroshima city hospital0 个研究点目标入组 40 人开始时间: 2013年1月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) with history of cardiac dysfunction 2) with sever complications ex.)with incontrollable diabetes,with infection,hypertension, renal insufficiency, liver failure and mental disorder which become problem on clinical practice 3) during pregnancy or lactation 4) with active secondary malignancy (current secondary malignancy or other malignancy within 5 years) . 5) with bilateral breast cancer 6) with pulmonary fibrosis or pneumonitis 7) allergy of the nab-Paclitaxel, Epirubicin,Cyclophosphamide and Fluorouracil 8) with peripheral neuropathy 9) HBs antigen is positive 10) patients judged by the investigator as unfit to be enrolled in the study
研究者
相似试验
已完成
2 期
Phase II study of Nab-paclitaxel followed by FEC as neoadjuvant chemotherapy for the operable breast cancerbreast cancerJPRN-UMIN000011048Kitasato University Kitasato Institute Hospital20
招募中
2 期
Phase II study of FEC followed by Nab-paclitaxel as Neoadjuvant Chemotherapy for Primary Breast Cancerbreast cancerJPRN-UMIN000006428Toho University Omori Medical Center40
招募中
2 期
Phase II study of FEC followed by Nab-paclitaxel as Neoadjuvant Chemotherapy for Primary Breast CancerBreast cancerJPRN-UMIN000009152Toho University Omori Medical Center40
已完成
2 期
PhaseII study of Nab-paclitaxel followed by EC as neoadjuvant chemotherapy for the operable breast cancerBreast cancerJPRN-UMIN000022931Rakuwakai Otowa Hospital Breast oncology department24
招募中
2 期
A Phase II trial of nab-paclitaxel followed by EC as neoadjuvant chemotherapy for resectable breast cancer.breast cancerJPRN-UMIN000017382Tokyo Women's Medical University,Department of endocrine surgery36